Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fruquintinib→

Fruquintinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1194506-26-7
Molecular formula
C21H19N3O5
Molecular weight
393.4 g/mol
Drug class
Selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorantineoplastic
Mechanism of action
Inhibits VEGFR1, VEGFR2 and VEGFR3 kinase activity, suppressing angiogenesis and tumour-associated vascular signalling.
Indications / reported uses
  • Treatment of adults with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy and, if RAS wild-type, anti-EGFR therapy, under the applicable US product indication

Sources: US DailyMed — FRUZAQLA (fruquintinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fruquintinib Environmental Risk Assessment (ERA) (the Fruquintinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.